ATE446754T1 - Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten - Google Patents

Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten

Info

Publication number
ATE446754T1
ATE446754T1 AT05732721T AT05732721T ATE446754T1 AT E446754 T1 ATE446754 T1 AT E446754T1 AT 05732721 T AT05732721 T AT 05732721T AT 05732721 T AT05732721 T AT 05732721T AT E446754 T1 ATE446754 T1 AT E446754T1
Authority
AT
Austria
Prior art keywords
gluco
schizophrenia
compounds
treatment
regulatory disorders
Prior art date
Application number
AT05732721T
Other languages
English (en)
Inventor
Craig Smith
David Rampe
Beth Borowsky
Sathapana Kongsamut
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE446754T1 publication Critical patent/ATE446754T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05732721T 2004-04-01 2005-04-01 Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten ATE446754T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55845104P 2004-04-01 2004-04-01
PCT/US2005/011107 WO2005097122A2 (en) 2004-04-01 2005-04-01 Method of treating schizophrenia and/or glucoregulatory abnormalities

Publications (1)

Publication Number Publication Date
ATE446754T1 true ATE446754T1 (de) 2009-11-15

Family

ID=34978926

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732721T ATE446754T1 (de) 2004-04-01 2005-04-01 Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten

Country Status (26)

Country Link
US (1) US20070129403A1 (de)
EP (2) EP1734959B1 (de)
JP (1) JP2007531730A (de)
KR (1) KR20070010161A (de)
CN (1) CN1946399A (de)
AR (1) AR048197A1 (de)
AT (1) ATE446754T1 (de)
AU (1) AU2005231446A1 (de)
BR (1) BRPI0509512A (de)
CA (1) CA2561162A1 (de)
CL (1) CL2009001605A1 (de)
CY (1) CY1109734T1 (de)
DE (1) DE602005017373D1 (de)
DK (1) DK1734959T3 (de)
DO (1) DOP2005000050A (de)
ES (1) ES2334241T3 (de)
GT (1) GT200500063A (de)
IL (1) IL178168A0 (de)
MX (1) MXPA06011222A (de)
PA (1) PA8628601A1 (de)
PL (1) PL1734959T3 (de)
PT (1) PT1734959E (de)
SI (1) SI1734959T1 (de)
SV (1) SV2006002069A (de)
TW (1) TW200602040A (de)
WO (1) WO2005097122A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
CL2007002953A1 (es) * 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
RU2011119626A (ru) 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
WO2010068750A2 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
DK2437744T3 (en) * 2009-06-03 2015-07-27 Univ Marquette The modulation of the KCNQ potassium channel activity for the treatment of psychiatric disorders and symptoms thereof
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2488531B1 (de) 2009-10-14 2014-03-26 Xenon Pharmaceuticals Inc. Verfahren zur herstellung von spiro-oxindol derivaten
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CN103512972A (zh) * 2013-07-29 2014-01-15 上海交通大学 精神分裂症的生物标志物及其使用方法和应用
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
KR101759122B1 (ko) 2015-08-07 2017-07-18 계명대학교 산학협력단 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물
MX2019002265A (es) 2016-08-24 2019-10-30 Prilenia Therapeutics Dev Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
CN113840569A (zh) * 2019-03-19 2021-12-24 剑桥认知有限公司 诊断精神病症和推荐用于精神病症的治疗的方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US4970218A (en) 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (de) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(Pyridinyl)-1H-indol-1-amine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
US5102891A (en) * 1990-07-23 1992-04-07 Hoechst-Roussel Pharmaceuticals Inc. 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
US5356910A (en) * 1993-07-19 1994-10-18 Hoechst-Roussel Pharmaceuticals Inc. Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder
CA2225156C (en) * 1995-07-27 2003-06-10 Hoechst Marion Roussel, Inc. Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Also Published As

Publication number Publication date
BRPI0509512A (pt) 2007-09-11
JP2007531730A (ja) 2007-11-08
SI1734959T1 (sl) 2010-02-26
AR048197A1 (es) 2006-04-05
WO2005097122A3 (en) 2006-02-02
DOP2005000050A (es) 2005-11-30
GT200500063A (es) 2005-10-14
PT1734959E (pt) 2009-12-24
DE602005017373D1 (de) 2009-12-10
CN1946399A (zh) 2007-04-11
EP2138176A1 (de) 2009-12-30
MXPA06011222A (es) 2007-01-16
TW200602040A (en) 2006-01-16
PL1734959T3 (pl) 2010-03-31
CY1109734T1 (el) 2014-09-10
EP1734959B1 (de) 2009-10-28
CL2009001605A1 (es) 2009-11-27
PA8628601A1 (es) 2006-05-16
DK1734959T3 (da) 2010-03-08
EP1734959A2 (de) 2006-12-27
SV2006002069A (es) 2006-05-24
ES2334241T3 (es) 2010-03-08
IL178168A0 (en) 2006-12-31
WO2005097122A2 (en) 2005-10-20
CA2561162A1 (en) 2005-10-20
US20070129403A1 (en) 2007-06-07
AU2005231446A1 (en) 2005-10-20
KR20070010161A (ko) 2007-01-22

Similar Documents

Publication Publication Date Title
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
DE602006006354D1 (de) Pinolensäure zur Behandlung von Übergewicht
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE602005023452D1 (de) Mit calcitriol und clobetasolpropionat zur behandlung von schuppenflechte
DE602005014145D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1734959

Country of ref document: EP

REN Ceased due to non-payment of the annual fee